# Masahiro Fukuoka

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/masahiro-fukuoka/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,316 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 63 |
| i10-index | 178 |
| Last Known Institution | National Institute of Standards and Technology |
| OpenAlex ID | https://openalex.org/A5108393803 |
| Works | 374 |

## Researcher papers

- [Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma](https://scholariq.org/papers/gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma/)
- [Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)](https://scholariq.org/papers/biomarker-analyses-and-final-overall-survival-results-from-a-phase-iii/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Interstitial Lung Disease in Japanese Patients with Lung Cancer](https://scholariq.org/papers/interstitial-lung-disease-in-japanese-patients-with-lung-cancer/)
- [Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-v-15-32-of-gefitinib-versus-docetaxel-in-previously-treated/)
- [Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-first-line-carboplatin-paclitaxel-with-or-without/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

## Researcher university

- [National Institute of Standards and Technology](https://scholariq.org/institutions/national-institute-of-standards-and-technology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.